Lumicell
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lumicell sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Lumicell: 8 sponsored US clinical trials, 1 recruiting.
Lumicell sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastric Cancer, with 1 trials.
Upper-quartile sponsor footprint
Lumicell sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
NCT04440982
Investigation of Novel Surgical Imaging for Tumor Excision
NCT03686215
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
NCT03717142
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
NCT03441464
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
NCT03834272
Intraoperative Detection of Residual Cancer in Breast Cancer
NCT03321929
Feasibility Study of Intraoperative Imaging in Breast Cancer
NCT02438358
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Lumicell pipeline
1 recruiting of 8 indexed (13% open); 4 completed (50%).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Gastric Cancer (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lumicell: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Lumicell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Lumicell page
8 registered trials is a research-attention snapshot, not an endorsement of Lumicell or any single study.
- 1 of Lumicell's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Gastric Cancer is the condition Lumicell studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastric Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lumicell pipeline card: 8 registered trials from official public datasets.Report a data error.